Search

Your search keyword '"Gabrielle Bouchard"' showing total 4 results
Start Over Author "Gabrielle Bouchard" Journal cancer cell
4 results on '"Gabrielle Bouchard"'

1. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Author

Sarah Wall, Babar Bashir, Toni K. Choueiri, Salvatore Del Prete, Grace Shaw, Solange Peters, Catherine Curran, Navid Hafez, Nathaniel Bouganim, Sarah Nagle, Julie Tsu-Yu Wu, Jared D. Acoba, Vaibhav Kumar, Gabrielle Bouchard, Lisa Weissmann, Hagen F. Kennecke, Tian Zhang, Manmeet Ahluwalia, Sanjay Goel, Samuel M. Rubinstein, Daruka Mahadevan, Elizabeth A. Griffiths, Destry J. Elms, Michael J. Gurley, Arturo Loaiza-Bonilla, Suki Subbiah, Gilberto Lopes, Lisa Tachiki, David M. Aboulafia, Kent Hoskins, Daniel W. Bowles, Sandeep H. Mashru, Matthew Puc, Prakash Peddi, Nathan A. Pennell, Stephen V. Liu, Justin F. Gainor, Ali Raza Khaki, Rebecca L. Zon, Matthew D Tucker, Amanda Nizam, Bryan A. Faller, Deborah B. Doroshow, Nitin Ohri, Brian I. Rini, Abdul-Hai Mansoor, Sachin R. Jhawar, George D. Demetri, Catherine Stratton, Eliezer M. Van Allen, Praveen Vikas, Alvaro G. Menendez, Amelie G. Ramirez, Jonathan M. Loree, Divaya Bhutani, Clarke A. Low, Anju Nohria, Melissa K. Accordino, Rohit Bishnoi, Pamela C Egan, Rachel P. Rosovsky, Julie C. Fu, Fiona Busser, Orestis A. Panagiotou, Aditya Bardia, Peter Paul Yu, Susan Van Loon, Genevieve M. Boland, Douglas B. Johnson, Anup Kasi, Barbara Logan, Alice Zhou, Matthew D. Galsky, Arielle Elkrief, Mary Salazar, Rosemary Zacks, Carmen C. Solorzano, Andrew Schmidt, Paolo Caimi, Zhuoer Xie, Michael T. Schweizer, Briana Barrow McCollough, Jessica K. Altman, Christopher McNair, Cassandra Hennessy, Angelo Cabal, Qamar Ul Zaman, Alex Cheng, Keith Stockerl-Goldstein, John C. Leighton, Joshua D. Palmer, Scott J. Dawsey, Deepak Ravindranathan, Jonathan Riess, Miriam Santos Dutra, Daniel Blake Flora, Aakash Desai, Rana R. McKay, Ruben A. Mesa, Maheen Z. Abidi, Cathleen Park, Jill S. Barnholtz-Sloan, Erin Cook, Trisha Wise-Draper, Shannon K. McWeeney, Donald C. Vinh, Clara Hwang, Stephanie Berg, Leyre Zubiri, Daniel G. Stover, Michelle Marcum, Sarah Mushtaq, Wilhelmina D. Cabalona, Eyob Tadesse, Kanishka G. Patel, Ryan Monahan, Ziad Bakouny, Pankil Shah, David Gill, Terence Duane Rhodes, Marc A. Rovito, Chih-Yuan Hsu, Elizabeth T. Loggers, Shilpa Gupta, Susie Owenby, Benjamin A. Gartrell, David D. Chism, Neeta K. Venepalli, Punita Grover, Adam J. Olszewski, Sonya A. Reid, Firas Wehbe, Omar Butt, Emily Hsu, Poorva Bindal, Paul L. Weinstein, Jessica Hawley, Tanya M. Wildes, Subha Madhavan, Claire Hoppenot, Margaret E. Gatti-Mays, Huili Zhu, Michael Glover, Rawad Elias, Elizabeth S. Nakasone, Heather H. Nelson, Gerald Batist, Gary H. Lyman, John F. Deeken, Michael H. Bar, Pamela Bohachek, Benjamin French, Mark A. Lewis, Daniel J. Hausrath, Mary F. Mulcahy, X. Li, David A. Slosky, Michael J. Wagner, Nicole Williams, Hina Khan, Grace Glace, Jessica M. Clement, Pier Vitale Nuzzo, Petros Grivas, Brett A. Schroeder, Tanios Bekaii-Saab, John M. Nakayama, Vasil Mico, Young Soo Rho, Chaim Miller, Amit Verma, Kaitlin M. Kelleher, Elwyn C. Cabebe, William A. Wood, Elizabeth J. Davis, Anne H. Angevine, Cristiano Ferrario, Shaveta Vinayak, Jerome J. Graber, Monika Joshi, Danielle A. Shafer, Mary M. Pasquinelli, Mark Bonnen, Shirish M. Gadgeel, Balazs Halmos, Lucy L. Wang, Dawn L. Hershman, Sana Z. Mahmood, Dimpy P. Shah, Maryam B. Lustberg, Albert C. Yeh, Eric H. Bernicker, Mitrianna Streckfuss, Leslie A. Fecher, Clement Pillainayagam, Karen Stauffer, Gayathri Nagaraj, Dimitrios Farmakiotis, Elizabeth Marie Wulff-Burchfield, Chintan Shah, Sibel Blau, Ryan H. Nguyen, Lane R. Rosen, Robert L. Rice, Mark E. Dailey, Melanie J. Clark, Goetz Kloecker, Alicia K. Morgans, Cameron Rink, Umit Topaloglu, Mark A. Fiala, Saif I. Alimohamed, Gary K. Schwartz, Jessica Yasmine Islam, Bertrand Routy, James L. Chen, Oscar K. Serrano, Chinmay Jani, Shuchi Gulati, K.M. Lo, Alokkumar Jha, Anthony P. Gulati, Lori J. Rosenstein, Roy S. Herbst, Matthias Weiss, Justin Shaya, Philip E. Lammers, Irene S. Yu, Syed A. Ahmad, Salma K. Jabbour, Erin A. Gillaspie, Irma Hoyo-Ulloa, Jordan Kharofa, Jean M. Connors, Daniel Mundt, Christopher R. Friese, Ryan C. Lynch, Mansi R. Shah, Howard Zaren, M. Wasif Saif, Gerald Gantt, Lawrence E. Feldman, Jian Campian, Daniel Y. Reuben, Sanjay G. Revankar, Merry Jennifer Markham, Melissa Smits, Patricia LoRusso, Thorvardur R. Halfdanarson, Christine Pilar, Eric B. Durbin, Blanche Mavromatis, Yu Shyr, Jaymin M. Patel, Candice Schwartz, Ang Li, Antonio Giordano, Amit Kulkarni, Joerg Rathmann, Harry Menon, Amro Elshoury, Mahir Khan, Theresa M. Carducci, Susan Halabi, Sumit A. Shah, Jeremy L. Warner, Mehmet Asim Bilen, Kerry L. Reynolds, Michael A. Thompson, Ahmad Daher, Lidia Schapira, Eneida R. Nemecek, Sanjay Mishra, Jamie Stratton, Karen Vega-Luna, Tyler Masters, Corrie A. Painter, Archana Ajmera, Jorge A. Garcia, Wenxin Xu, Christopher Lemmon, and Jeanna Knoble

Subjects
0301 basic medicine, Cancer Research, Quality management, MEDLINE, 03 medical and health sciences, COVID-19 Testing, 0302 clinical medicine, Neoplasms, Pandemic, medicine, Electronic Health Records, Humans, Protocol (science), SARS-CoV-2, business.industry, Corporate governance, COVID-19, Cancer, Cell Biology, medicine.disease, Quality Improvement, Data Accuracy, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Scale (social sciences), Commentary, Business, Medical emergency, Quality assurance
Abstract

When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.

Published
2020
Full Text
View/download PDF

2. Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study

Author

Mark M. Awad, Fiona Busser, Talia D. Rosenbloom, Michelle Evans, Brittney S Zimmerman, Kaitlin M. Kelleher, Toni K. Choueiri, Robert I. Haddad, Douglas Tremblay, Danielle Seidman, Michael Wotman, Alaina J. Kessler, Sheena Bhalla, Ziad Bakouny, Catherine Curran, Pier Vitale Nuzzo, Jonathan Feld, Gabrielle Bouchard, Deborah B. Doroshow, Penina S. Stewart, Hsin-Hui Huang, Matthew D. Galsky, Qian Qin, Andrew Schmidt, Heather M. Anderson-Keightly, Sarah Abou Alaiwi, John A. Steinharter, Laure Hirsch, and Tomi Jun

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, 2019-20 coronavirus outbreak, Letter, Time Factors, Coronavirus disease 2019 (COVID-19), MEDLINE, Medical Oncology, Time-to-Treatment, Young Adult, Neoplasms, Epidemiology, Pandemic, Medicine, Humans, Prospective Studies, Young adult, Healthcare Disparities, Prospective cohort study, Pandemics, Aged, Aged, 80 and over, business.industry, SARS-CoV-2, Cancer, COVID-19, Cell Biology, Middle Aged, medicine.disease, Telemedicine, Oncology, Family medicine, Communicable Disease Control, Female, business, Follow-Up Studies
Published
2020

3. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Author

Sébastien Vigneau, Bradley Alexander McGregor, Ziad Bakouny, John A. Steinharter, Toni K. Choueiri, Orit Rozenblatt-Rosen, Eliezer M. Van Allen, Grace Grimaldi, Erin Shannon, Sabina Signoretti, Alok K. Tewari, Aviv Regev, Abhay Kanodia, Gabrielle Bouchard, Jihye Park, Thomas Denize, Rizwan Haq, Michael S. Cuoco, Angie Mayorga, Meng Xiao He, Jingyi Wu, Asaf Rotem, Maxine Sun, David A. Braun, Kevin Bi, Laura DelloStritto, Jennifer L. Guerriero, Natalie I. Vokes, Steven L. Chang, and Sara Napolitano

Subjects
0301 basic medicine, kidney, Cancer Research, medicine.medical_treatment, Cell, Article, resistance, 03 medical and health sciences, 0302 clinical medicine, Immune system, Renal cell carcinoma, medicine, Tumor Microenvironment, cancer, Cytotoxic T cell, Humans, Immunologic Factors, Carcinoma, Renal Cell, business.industry, Cancer, Immunotherapy, medicine.disease, Immune checkpoint, Kidney Neoplasms, single cell, DNA-Binding Proteins, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Cancer cell, Cancer research, business, Transcription Factors
Abstract

Summary Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before or after ICB exposure. In responders, subsets of cytotoxic T cells express higher levels of co-inhibitory receptors and effector molecules. Macrophages from treated biopsies shift toward pro-inflammatory states in response to an interferon-rich microenvironment but also upregulate immunosuppressive markers. In cancer cells, we identify bifurcation into two subpopulations differing in angiogenic signaling and upregulation of immunosuppressive programs after ICB. Expression signatures for cancer cell subpopulations and immune evasion are associated with PBRM1 mutation and survival in primary and ICB-treated advanced RCC. Our findings demonstrate that ICB remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations critical for understanding response and resistance to ICB., Graphical abstract, Highlights • Distinct CD8+ T cell phenotypes are enriched after immune checkpoint blockade (ICB) • Immune checkpoint ligands are upregulated in macrophages and tumor cells after ICB • Two cancer cell subpopulations are conserved across heterogeneous RCC tumors • Cancer cell programs drive distinct immune interactions and predict patient outcomes, Bi et al. dissect the cancer cell and immune microenvironmental transcriptional programs in immune checkpoint blockade-exposed metastatic renal cell carcinoma, revealing immune subpopulation reprogramming and interactions with distinct cancer cell populations in the context of clinical resistance.

Published
2020

4. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

Author

Gabrielle Bouchard, Wenxin Xu, David L. Cookmeyer, Bradley Alexander McGregor, Kelly Street, Ziad Bakouny, Arlene H. Sharpe, Christina B. Pedersen, Lucas Pomerance, Nicholas Schindler, Sachet A. Shukla, Erica Maria Pimenta, Rafael A. Irizarry, Kathleen M. Mahoney, John A. Steinharter, Ang Cui, Kelly P. Burke, Juliet Forman, Steven L. Chang, Michelle S. Hirsch, Maxine Sun, Catherine J. Wu, Lars Rønn Olsen, Sabina Signoretti, David A. Braun, Derin B. Keskin, Toni K. Choueiri, Kenneth J. Livak, Shuqiang Li, Yue Hou, David F. McDermott, Satyen H. Gohil, Teddy Huang, Laure Hirsch, and Thomas Denize

Subjects
0301 basic medicine, Cancer Research, Myeloid, medicine.medical_treatment, Article, 03 medical and health sciences, 0302 clinical medicine, Immune system, Cell–cell interaction, Cancer immunotherapy, medicine, Humans, Carcinoma, Renal Cell, business.industry, Cancer, Immunotherapy, medicine.disease, Kidney Neoplasms, Clear cell renal cell carcinoma, 030104 developmental biology, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Cancer research, business, CD8
Abstract

The tumor immune microenvironment plays a critical role in cancer progression and response to immunotherapy in clear cell renal cell carcinoma (ccRCC), yet the composition and phenotypic states of immune cells in this tumor are incompletely characterized. We performed single-cell RNA and T cell receptor sequencing (scRNA-seq/scTCR-seq) on 164,722 individual cells from tumor and adjacent non-tumor tissue in patients with ccRCC across disease stages – early, locally advanced, and advanced/metastatic. Terminally exhausted CD8(+) T cells were enriched in metastatic disease and were restricted in TCR diversity. Within the myeloid compartment, pro-inflammatory macrophages were decreased, and suppressive M2-like macrophages were increased in advanced disease. Terminally exhausted CD8(+) T cells and M2-like macrophages co-occurred in advanced disease and expressed ligands and receptors that support T cell dysfunction and M2-like polarization. This immune dysfunction circuit is associated with a worse prognosis in external cohorts and identifies potentially targetable immune inhibitory pathways in ccRCC.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results